Wells Fargo & Company upgraded shares of Medidata Solutions (NASDAQ:MDSO) from a market perform rating to an outperform rating in a report issued on Friday morning. Wells Fargo & Company currently has $80.00 target price on the stock.

A number of other equities analysts also recently issued reports on the company. Dougherty & Co upgraded Medidata Solutions from a neutral rating to a buy rating and set a $75.00 price target on the stock in a research note on Monday, November 13th. Zacks Investment Research upgraded Medidata Solutions from a sell rating to a hold rating in a research note on Friday, November 10th. Royal Bank Of Canada restated a hold rating and issued a $80.00 price target on shares of Medidata Solutions in a research note on Friday, October 27th. SunTrust Banks restated a buy rating and issued a $92.00 price target on shares of Medidata Solutions in a research note on Friday, October 27th. Finally, KeyCorp reiterated a buy rating and set a $86.00 target price on shares of Medidata Solutions in a research report on Sunday, September 17th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $83.54.

Medidata Solutions (NASDAQ MDSO) traded up $0.71 during mid-day trading on Friday, hitting $67.35. The stock had a trading volume of 592,072 shares, compared to its average volume of 640,291. The stock has a market cap of $3,895.84, a P/E ratio of 80.29, a P/E/G ratio of 4.15 and a beta of 1.71. Medidata Solutions has a 52-week low of $47.77 and a 52-week high of $85.92. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61.

Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings results on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.02. The firm had revenue of $140.08 million for the quarter, compared to the consensus estimate of $141.27 million. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS. sell-side analysts expect that Medidata Solutions will post 0.77 earnings per share for the current year.

In related news, Director Robert Taylor sold 5,000 shares of Medidata Solutions stock in a transaction on Monday, November 6th. The stock was sold at an average price of $71.39, for a total transaction of $356,950.00. Following the transaction, the director now directly owns 49,372 shares in the company, valued at $3,524,667.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Tarek Sherif sold 200,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $68.76, for a total value of $13,752,000.00. The disclosure for this sale can be found here. Insiders have sold 225,944 shares of company stock worth $15,568,274 over the last quarter. 5.80% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the company. Fortaleza Asset Management Inc. purchased a new position in shares of Medidata Solutions in the third quarter valued at about $155,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Medidata Solutions by 10.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after acquiring an additional 208 shares in the last quarter. Polen Capital Management LLC purchased a new position in shares of Medidata Solutions in the third quarter valued at about $205,000. Cubist Systematic Strategies LLC purchased a new position in shares of Medidata Solutions in the second quarter valued at about $227,000. Finally, ETF Managers Group LLC purchased a new position in shares of Medidata Solutions in the second quarter valued at about $233,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/12/02/medidata-solutions-mdso-upgraded-to-outperform-by-wells-fargo-company.html.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.